Private Swiss biotechs hit record funding amid slowdown in public financing
Funding for privately traded Swiss biotechs hit a new high last year, climbing 38% to 1.15 billion Swiss francs ($1.5 billion). However, a relatively small pool...
Funding for privately traded Swiss biotechs hit a new high last year, climbing 38% to 1.15 billion Swiss francs ($1.5 billion). However, a relatively small pool of companies drove the funding jump while many of their peers raised nothing, echoing the global gap between the haves and have-nots.